Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| JAGX | 8-K | mixed | 6/10 | Jaguar Health entered into exchange agreements with Uptown Capital and Streeterville Capital, issuing 908 shares of newl | May 19, 2026 |
| CLRB | S-1 | bearish | 6/10 | Cellectar Biosciences filed an S-1 registration statement to register up to 51.2 million shares of common stock for resa | May 19, 2026 |
| GOVX | 8-K | bearish | 7/10 | GeoVax Labs entered into a securities purchase agreement to sell common stock at $1.48 per share and issue Series A (5-y | May 19, 2026 |
| MEHA | DEFA14A | mixed | 7/10 | Functional Brands Inc. (MEHA) filed a DEFA14A soliciting shareholder support for a proposed all-stock acquisition of Bul | May 19, 2026 |
| ACOG | CLUSTER | bullish | 5/10 | Two insiders at Alpha Cognition (ACOG) made open-market purchases totaling ~$119K over a 7-day window. The COO bought $2 | May 19, 2026 |
| CRDF | 8-K | bearish | 5/10 | Cardiff Oncology filed a lawsuit against Nerviano Medical Sciences (NMS) to preemptively challenge NMS's allegation that | May 19, 2026 |
| CNSP | S-3 | bearish | 7/10 | CNS Pharmaceuticals filed a resale S-3 registering up to 9,793,479 shares (650,000 common + 9,143,479 pre-funded warrant | May 19, 2026 |
| VXRT | DEFA14A | mixed | 6/10 | Vaxart filed preliminary proxy materials and issued an open letter to shareholders ahead of its July 16, 2026 Annual Mee | May 19, 2026 |
| ARDX | 144 | neutral | 2/10 | Officer John E. Bishop filed a Form 144 to sell 3,700 shares of Ardelyx common stock (~$23,000) as an automatic sell-to- | May 19, 2026 |
| AURA | PRESS-RELEASE | neutral | 3/10 | Aura Biosciences granted inducement equity awards to new CEO Natalie Holles, consisting of stock options, RSUs, and perf | May 19, 2026 |
| CINGW | 8-K | neutral | 2/10 | Cingulate reported that Class II directors Jeff Ervin and Jay Roberts will not stand for re-election at the 2026 Annual | May 19, 2026 |
| ETON | 8-K | bullish | 6/10 | Eton Pharmaceuticals entered into a supply and distribution agreement for exclusive U.S. commercialization rights to IMP | May 19, 2026 |
| ELAN | CLUSTER | bullish | 5/10 | CEO Jeffrey Simmons and executive Rajeev Modi made open-market purchases totaling ~$200K on May 15, 2026, just 9 days af | May 19, 2026 |
| UTHR | CLUSTER | neutral | 2/10 | UTHR's CEO, CFO, and a director sold shares worth $271K in aggregate over a week following Q1 2026 earnings that showed | May 19, 2026 |
| BBIO | CLUSTER | neutral | 3/10 | A cluster of insider selling at BridgeBio Pharma (BBIO) occurred in the week following the Q1 2026 earnings release and | May 19, 2026 |
| VTGN | 8-K | neutral | 4/10 | Vistagen appointed Dr. Angel S. Angelov as Chief Medical Officer effective May 18, 2026, with a base salary of $425,000, | May 19, 2026 |
| ZLAB | CLUSTER | bearish | 6/10 | CEO Du Ying sold $3.3M worth of ZLAB shares over a 5-day window, primarily through same-day option exercises and open-ma | May 19, 2026 |
| ARTV | PRESS-RELEASE | bullish | 8/10 | Artiva Biotherapeutics announced five data presentations at the EULAR 2026 Congress (June 3-6, 2026) for its AlloNK (AB- | May 19, 2026 |
| AMGN | 8-K | neutral | 3/10 | Amgen CFO Peter Griffith is retiring effective August 31, 2026, with a transition period through January 2027. Thomas Di | May 19, 2026 |
| BCRX | CLUSTER | neutral | 3/10 | Two BioCryst insiders sold a total of $697K in open-market sales within a week of Q1 2026 earnings. The CLO exercised 62 | May 19, 2026 |
| VRTX | CLUSTER | neutral | 2/10 | Two EVP-level insiders at Vertex (CMO and Chief Scientific Officer) sold open-market shares on the same day for a combin | May 19, 2026 |
| MCRB | CLUSTER | neutral | 2/10 | Four corporate officers and one director sold a total of 474 shares for ~$3,569 in open-market transactions on May 18, 2 | May 19, 2026 |
| KALV | CLUSTER | neutral | 2/10 | Two C-suite insiders, the CEO and CMO of KalVista, made nominal open-market sales totaling $58K (-0.004% of $1.4B market | May 19, 2026 |
| RLAY | PRESS-RELEASE | bearish | 7/10 | Relay Therapeutics announced a $175 million underwritten public offering of common stock, with an additional 15% option | May 19, 2026 |
| GRTX | 8-K | bearish | 8/10 | Galera Therapeutics converted its remaining 42,839.11 shares of Series B Non-Voting Convertible Preferred Stock into 42, | May 19, 2026 |
| ACHV | PRESS-RELEASE | bullish | 7/10 | Achieve Life Sciences presented comprehensive long-term safety data from the ORCA-OL study at ATS 2026, showing cytisini | May 19, 2026 |
| PEPG | S-3 | bearish | 7/10 | PepGen filed a new universal shelf registration statement (S-3) for up to $400M in securities, including a $100M ATM fac | May 19, 2026 |
| SBFMW | 424B4 | bearish | 6/10 | Sunshine Biopharma has completed a $6.0 million priced offering, issuing 11,160,000 Common Units (each with one share of | May 19, 2026 |
| ASND | ANALYST-UPGRADE | bullish | 3/10 | Citigroup initiated coverage on Ascendis Pharma A/S (ASND) with a Buy rating and a $355 price target, representing 44.6% | May 19, 2026 |
| INM | 425 | mixed | 7/10 | InMed Pharmaceuticals (INM) entered into a definitive reverse merger agreement with Mentari Therapeutics, where Mentari | May 19, 2026 |